The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/I...
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings ...
Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results o...
Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first...
The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients wit...
Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In additio...
Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast ...
In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression can be combined with tamoxifen or an aromatase inhibitor. A meta-analysis of 4 randomized co...
Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A meta-analysis based on data of 18,203 participants now demonstrates anthracycline/taxane to r...
Both adjuvant therapy with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have shown to improve progression-free survival in patients with HER2-positive, metastatic breast ...
Among patients with HR-positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed rising ESR1 mutations before disease progression doubled their median ...
Regular physical activity (PA) and healthy body weight have proven benefits on survival in breast cancer (BC) survivors. We aimed to define predictors of long-term PA and weight gain in a re...
“The optimal adjuvant therapy for women with advanced endometrial cancer remains controversial,” says Gretchen Glaser, MD. “It is unclear how to best sequence adjuvant chemotherapy and...
“Racial inequity in healthcare delivery and outcomes in the United States is well-documented, and outcomes for breast and gynecologic cancers are no exception,” explains Katherine V. Gre...
Oxoplatin-B, a platinum(IV) complex [Pt(NH)Cl(L)(OH)] (1) of 4-methylbenzoic acid (HL) functionalized with 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) was prepared, characterized and...
Over the last decade, there has been significant developments in nanotechnology, in particular for combined imaging and therapeutic applications (theranostics). The core or shell of nanoemul...
International guidelines do not recommend magnetic resonance imaging (MRI) for all breast cancer patients at primary diagnostics. This study aimed to understand which patient or tumor charac...
Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT).We ana...
Public health organizations release new recommendations as pandemic rages on The CDC and other public health entities recently issued a host of new Covid-19 guidance, with recommendations c...
The expression “It shouldn’t have to happen to you to matter to you” has been making the rounds on social media platforms lately. In my opinion, it’s a great way to define empathy, o...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
